Search and filter stories that passed editorial review. Evidence strength, regulatory status, and guideline position are shown separately and are never inferred from one another.
In the randomized, phase 3 PANOVA-3 trial, adding Tumor Treating Fields (TTFields) -- a wearable device that emits alternating electric fields through skin-worn arrays -- to standard chemotherapy significantly extended…
In the single-arm Study ASTX727-07, an all-oral combination of decitabine/cedazuridine (Inqovi) plus venetoclax produced a complete remission rate of 41.6% (and a combined complete-remission-or-partial-hematologic-recovery rate of 52.5%) in older or…